tallimustine

structure given in first source

Also Known As:

FCE 24517; FCE-24517; N-deformyl-N-(4-N-N,N-bis(2-choroethylamino)benzoyl)distamycin; 1H-Pyrrole-2-carboxamide, N-(5-(((3-amino-3-iminopropyl)amino)carbonyl)-1-methyl-1H-pyrrol-3-yl)-4-(((4-((4-(bis(2-chloroethyl)amino)benzoyl)amino)-1-methyl-1H-pyrrol-2-yl)carbonyl)amino)-1-methyl-

Networked: 23 relevant articles (0 outcomes, 6 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Geroni, C: 2 articles (10/2003 - 07/2000)
2.	Cozzi, P: 2 articles (05/2001 - 07/2000)
3.	Fedier, A: 1 article (10/2003)
4.	Fink, D: 1 article (10/2003)
5.	Fowst, C: 1 article (10/2003)
6.	Haller, U: 1 article (10/2003)
7.	Marchini, S: 1 article (10/2003)
8.	Tursi, J: 1 article (10/2003)
9.	Baraldi, P G: 1 article (07/2000)
10.	Beria, I: 1 article (07/2000)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1998 - "In this Phase I clinical trial, patients with advanced solid tumors received i.v. bolus injections of tallimustine daily for 3 consecutive days. " 01/21/1993 - "N-deformyl-N-[4-N,N-bis(2-chloroethylamino)benzoyl] distamycin-A (FCE 24517) is a new cytotoxic anti-tumor agent in phase-1 clinical trials. " 06/01/1999 - "PNU 151807 possesses a good cytotoxic activity in in vitro growing cancer cells, even superior to that found for tallimustine. " 01/21/1993 - "The clone derived from the above subline (L1210/24517(2)) was resistant to FCE 24517, distamycin-A and other cytotoxic compounds bearing the distamycin-A skeleton, and fully sensitive to DX and other anti-tumor compounds involved in the multi-drug resistance mechanisms, with a complete disappearance of the mdr phenotype. " 01/21/1993 - "When L1210/24517(1) cells were implanted in vivo and evaluated for sensitivity to the same agents, resistance was observed only to FCE 24517 and partially to L-PAM, whereas DX had the same anti-tumor efficacy as on the sensitive line. "
2.	Leukemia 12/01/1997 - "On the basis of its dramatic activity in this preclinical study, a Phase I study of tallimustine at a starting dose of 300 microgram/m2/day for 3 days every 3-4 weeks was conducted in patients with refractory or relapsed leukemia. " 12/01/1997 - "The aim of this study was to evaluate the potential activity of tallimustine in leukemia. " 07/13/2000 - "All novel compounds, with one exception, showed in vitro activity against L1210 murine leukemia cell line comparable to or better than that of tallimustine. " 12/01/1997 - "In this study, we first investigated the efficacy and toxic effects of tallimustine, a distamycin-A derivative, in a human leukemia model in severe combined immunodeficient (SCID) mice. " 10/19/1999 - "In bulk DNA of intact human leukemia CEM cells, tallimustine formed 0.15 +/- 0.04 and 0.64 +/- 0.18 lesions/kbp at 5 and 50 microM, respectively. "
3.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/01/1996 - "We conclude that Tallimustine is an ineffective agent in previously treated small cell lung cancer." 11/01/1996 - "Tallimustine is inactive in patients with previously treated small cell lung cancer. " 11/01/1996 - "We conducted a phase II trial of Tallimustine given at a dose of 750 micrograms/m2 intravenously every 4 weeks in patients with small cell lung cancer progressing or relapsing following cisplatin or carboplatin-based chemotherapy. " 12/01/1991 - "The following neoplasms were in fact found to be sensitive to FCE 24517 treatment: M14 human melanoma xenograft, N592 human small cell lung carcinoma, MTV murine mammary carcinoma, Colon 38 murine carcinoma, PO2 murine pancreatic carcinoma and M5076 murine reticulosarcoma. "
4.	Leukemia L1210 01/21/1993 - "Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies." 05/28/1993 - "Intracellular glutathione (GSH) content was measured by flow cytometry using monochlorobimane (mBCl) and by the enzymatic assay in a set of 6 sublines of murine L1210 leukemia cells made resistant to DNA-interacting agents having distinct mechanisms of action: L-phenylalanine mustard (L-PAM), 1,3-bis(2-chloroethyl)-I-nitrosourea (BCNU), cisplatin (DDP), N-deformyl-N-(4-N,N-bis(2-chloroethylamino) benzoyl) distamycin A (FCE 24517), doxorubicin (DX) and 3'-deamino-3' (2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762). "
5.	Cardiotoxicity 11/15/1992 - "The cytotoxicity and cardiotoxicity of benzoyl mustard (FCE 24517) and epoxamido (FCE 24561) synthetic derivatives of distamycin A were reported in the present study. "

Related Drugs and Biologics

1.	stallimycin
2.	tallimustine
3.	Cisplatin (Platino)
4.	Carboplatin (JM8)
5.	FCE 24561
6.	Melphalan (Alkeran)
7.	DNA (Deoxyribonucleic Acid)
8.	Mechlorethamine (Nitrogen Mustard)
9.	Antineoplastic Agents (Antineoplastics)
10.	Benzoic Acid (Potassium Benzoate)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Injections
3.	Aftercare (After-Treatment)